Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B
Journal
Alimentary pharmacology & therapeutics
Journal Volume
59
Journal Issue
2
Date Issued
2024-01
Author(s)
Cheng, Pin-Nan
Feng, I-Cher
Chen, Jyh-Jou
Kuo, Hsing-Tao
Lee, Pei-Lun
Yu, Ming-Lung
Chiu, Yen-Cheng
Chiu, Hung-Chih
Chien, Shih-Chieh
Abstract
Lipid-lowering effect was observed during treatment with tenofovir disoproxil fumarate (TDF) for chronic hepatitis B (CHB). However, the metabolic features in patients switching from TDF to tenofovir alafenamide (TAF) remain unclear.
Subjects
blood lipid; hepatitis B virus; insulin resistance; tenofovir alafenamide
SDGs
Type
journal article